Cutler Group LP Immuno Gen, Inc. Transaction History

Cutler Group LP

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 18, 2024	BUY	$12.46 - $29.95 $41,118 - $98,835	3,300 Added 550.0%	3,900 $115,000
Q3 2023 Nov 07, 2023	BUY	$14.09 - $19.87 $1,409 - $1,987	100 Added 20.0%	600 $9,000
Q2 2023 Jul 18, 2023	BUY	$3.75 - $20.05 $1,875 - $10,025	500 New	500 $9,000
Q4 2022 Feb 07, 2023	BUY	$4.55 - $6.31 $34,639 - $48,038	7,613 Added 38.34%	27,472 $136,000
Q3 2022 Oct 25, 2022	BUY	$4.48 - $6.47 $52,680 - $76,080	11,759 Added 145.17%	19,859 $94,000
Q2 2022 Aug 04, 2022	BUY	$3.15 - $5.76 $13,860 - $25,344	4,400 Added 118.92%	8,100 $36,000
Q1 2022 Apr 14, 2022	BUY	$4.26 - $7.48 $11,502 - $20,196	2,700 Added 270.0%	3,700 $17,000
Q2 2021 Jul 19, 2021	BUY	$5.79 - $8.6 $5,790 - $8,600	1,000 New	1,000 $6,000
Q2 2019 Aug 09, 2019	SELL	$1.8 - $3.3 $25,920 - $47,520	-14,400 Closed	0 $0
Q1 2019 May 10, 2019	BUY	$2.41 - $5.91 $34,704 - $85,104	14,400 New	14,400 $39,000
Q2 2018 Aug 10, 2018	SELL	$9.52 - $12.15 $88,954 - $113,529	-9,344 Closed	0 $0
Q1 2018 May 11, 2018	BUY	$6.7 - $12.95 $50,585 - $97,772	7,550 Added 420.85%	9,344 $98,000
Q4 2017 Jan 17, 2018	SELL	$5.07 - $7.92 $13,100 - $20,465	-2,584 Reduced 59.02%	1,794 $11,000
Q3 2017 Oct 17, 2017	BUY	$5.4 - $8.47 $23,641 - $37,081	4,378	4,378 $33,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.